These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1557698)

  • 1. Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats.
    Chen J; Paredes W; Van Praag HM; Lowinson JH; Gardner EL
    Synapse; 1992 Mar; 10(3):264-6. PubMed ID: 1557698
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens.
    Chen JP; van Praag HM; Gardner EL
    Brain Res; 1991 Mar; 543(2):354-7. PubMed ID: 1711914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study.
    Ashby CR; Minabe Y; Edwards E; Wang RY
    Brain Res; 1991 Jun; 550(2):181-91. PubMed ID: 1679370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens.
    McNeish CS; Svingos AL; Hitzemann R; Strecker RE
    Pharmacol Biochem Behav; 1993 Aug; 45(4):759-63. PubMed ID: 8415815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue.
    Barnes JM; Barnes NM; Costall B; Naylor RJ; Tyers MB
    Nature; 1989 Apr; 338(6218):762-3. PubMed ID: 2524005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action of serotonin in the medial prefrontal cortex: mediation by serotonin3-like receptors.
    Ashby CR; Edwards E; Wang RY
    Synapse; 1992 Jan; 10(1):7-15. PubMed ID: 1536032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist.
    Invernizzi R; Pozzi L; Samanin R
    Neuropharmacology; 1995 Feb; 34(2):211-5. PubMed ID: 7617146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain.
    Waeber C; Pinkus LM; Palacios JM
    Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
    Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
    C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat.
    Costall B; Domeney AM; Naylor RJ
    Neuroreport; 1990 Sep; 1(1):77-80. PubMed ID: 1966601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
    Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
    Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zacopride, a potent 5-HT3 antagonist.
    Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L
    J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1990 Jul; 254(1):350-5. PubMed ID: 2366187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex.
    Chen J; Paredes W; Lowinson JH; Gardner EL
    Eur J Pharmacol; 1990 Nov; 190(1-2):259-62. PubMed ID: 1963849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist effects at putative central 5-HT4 receptors in rat hippocampus by R(+)- and S(-)-zacopride; no evidence for stereo-selectivity.
    Boddeke HW; Kalkman HO
    Neurosci Lett; 1992 Jan; 134(2):261-3. PubMed ID: 1589153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain.
    Fletcher S; Barnes NM
    Brain Res; 1996 Aug; 729(2):281-4. PubMed ID: 8877001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs.
    Gullikson GW; Loeffler RF; Viriña MA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):103-10. PubMed ID: 2072288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methamphetamine-induced dopamine release in the medial frontal cortex of freely moving rats.
    Kashihara K; Hamamura T; Okumura K; Otsuki S
    Jpn J Psychiatry Neurol; 1991 Sep; 45(3):677-80. PubMed ID: 1800816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.